Clinical Investigation Shows Herb-Pharma's ViroStop Spray Effective in Reducing Impact of Covid-19
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Dr István Jankovics, whose team ran the study commented, "The primary treatment for Covid 19 is, of course, vaccination, however this study means that the use of the ViroStop spray significantly inhibits the amount of SARS CoV-2 in the upper respiratory tract, thus providing an opportunity for the infected person to develop a specific immune response."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
ZURICH -- Businesswire -- A recent clinical study has shown that the ViroStop anti-viral spray from Swiss company, Herb-Pharma is effective in reducing the impact of Covid-19 for patients with mild to moderate symptoms.
The key benefits were a 60% reduction in viral shedding after using the treatment and a reduction in the severity of clinical respiratory symptoms. The study supports the findings of earlier in-vitro tests where its mix of polyphenols inhibited the growth of the virus in cell cultures.
The study included 170 PCR confirmed SARS-CoV-2 patients at the Complex Medical Clinic in Budapest, Hungary between January 15th, and May 31st, 2021. The volunteers all had mild to moderate respiratory symptoms, having tested positive in PCR tests for Covid-19 at the start of the study, and their symptoms were monitored over 12 days.
Of the 170 volunteers, 86 received a nasopharyngeal spray, the patented ViroStop solution, which contains a mixture of Cistus Creticus and other polyphenol-rich ingredients. Polyphenols when attached to viral protein, mechanically inhibit the workings of the protein, and thus stop the virus from entering the cell. The rest of the 84 patients remained in the control group and were not given the ViroStop solution. Each patient’s symptoms were checked every two days for 12 days.
At the end of the study the level of viral shedding was checked by PCR tests. Those patients who had used the ViroStop spray from the first day after testing positive, showed an almost 60% reduction in viral shedding on day 12, compared to the control group. The study showed that the severity of respiratory clinical symptoms was also reduced in those who used ViroStop spray.
A reduction was also noted in gastrointestinal symptoms compared to the control group. Recent research has shown that a key factor in the spread of the virus is its ability to also multiply in the gastrointestinal tract.
Dr István Jankovics, whose team ran the study commented, “The primary treatment for Covid 19 is, of course, vaccination, however this study means that the use of the ViroStop spray significantly inhibits the amount of SARS CoV-2 in the upper respiratory tract, thus providing an opportunity for the infected person to develop a specific immune response.”
ViroStop is a non-prescription treatment, made from natural ingredients and can be taken safely by children as young as three. Furthermore, at the time of the study, at least three variants of the virus were present in Hungary, so it is reasonable to assume that the solution and the action of polyphenols is effective against all known mutations of Covid-19.
Issued on behalf of:
Herb-Pharma AG Waldmannstrasse 6, 8001 Zurich, Switzerland
Company email: home@herb-pharma.com For more information visit: https://www.virostop.info/ Company website: https://www.fytofontana.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005309/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Herb-Pharma
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- ‘나보타 10년’ 대웅제약의 도전, 2030년엔 매출 5000억원 목표 - 뉴스와이어
- 한화그룹 김승연 회장, 한화금융계열사 찾아 ‘그레이트 챌린저’ 주문 - 뉴스와이어
- 대한항공, 7월 1일부터 인천~마카오 신규 취항 - 뉴스와이어
- 제네시스, GV70 부분변경 모델 디자인 공개 - 뉴스와이어
- LG화학, 중국 데상트 신발에 친환경 소재 적용 - 뉴스와이어
- 엔비피헬스케어, 알츠하이머병 생균치료제 ‘NVP-NK4146’ 치매극복연구개발사업 과제 선정 - 뉴스
- 보쉬, 하노버 산업 박람회 2024서 공장 자동화·수소 경제·AI 위한 지속가능한 솔루션 제시… 지속
- 넥센타이어, 현대 N 페스티벌 모터스포츠 대회에 공식 타이어 공급 - 뉴스와이어
- KOTRA 인베스트 코리아 ‘한-폴란드 비즈니스 포럼’ 개최 - 뉴스와이어
- 에이수스, 차세대 AMD 라이젠 프로세서 지원 메인보드 바이오스 업데이트 발표 - 뉴스와이어